$1.22
▼ -1.6% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
Overview
52-week range
$1.02
$4.98
5% of range
Avg surprise (last 3)
-14.7%
Avg reaction (last 2)
+16.6%
50% positive
Latest IV / EM
2135%
EM ±154.5% · $3 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $-0.21 | $-0.19 | -10.5% | +41.7% | -3.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.30 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.50 | $-0.36 | -38.9% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.36 | $-0.38 | +5.3% | — | +37.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.42 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.38 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.56 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.57 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.60 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.19 | -$0.50 | +62.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21M | — | $16M | $19M | $23M | — | $18M | $17M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-25M | — | $-31M | $-44M | $-28M | — | $-36M | $-29M |
| Net income | $-33M | — | $-41M | $-57M | $-39M | — | $-44M | $-37M |
| EPS (diluted) | $-0.21 | — | $-0.30 | $-0.50 | $-0.36 | — | $-0.42 | $-0.38 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $231M | $261M | $235M | $265M | $195M | $251M | $274M | $300M |
| Inventory | $5M | $4M | $18M | $18M | $17M | $18M | $16M | $15M |
| Total current assets | $277M | $306M | $287M | $319M | $258M | $307M | $333M | $355M |
| Total assets | $291M | $323M | $290M | $322M | $273M | $322M | $349M | $372M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $508M | $509M | $528M | $521M | $511M | $525M | $521M | $503M |
| Total equity | $-216M | $-186M | $-238M | $-199M | $-238M | $-203M | $-172M | $-132M |